MedTrace Logo

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

NCT07080567 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-08-12

No results posted yet for this study

Summary

MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.

Conditions

Interventions

DRUG

Maraviroc

Maraviroc (300mg) twice daily for 90 days

DRUG

Mannitol

Placebo intervention

Sponsors & Collaborators

  • Emmanuel Carrera

    lead OTHER

Principal Investigators

  • Emmanuel Carrera, MD · Hôpitaux Universitaires Genève

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-14
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07080567 on ClinicalTrials.gov